Please see new guidance from the UK Chemotherapy Board on ‘Personalised Medicine Approach For Fluoropyrimidine-based Therapies’.
Objective of document: To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
Full guidance can be accessed HERE or found in our resource center in the BOPA website.
4 Weeks left to nominate a BOPA Fellow for 2026. The BOPA Fellowship Scheme Policy has been updated for a clearer nomination and selection process including specific criteria for assessing the nominated individuals.…
Dear BOPA Member, Every day, oncology pharmacy professionals play a vital role in ensuring patients receive safe and effective SACT. Whether preparing, dispensing, transporting or supporting the administration of hazardous…
BOPA Publication: Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation – Annette (Netty) Cracknell, Dharmisha Chauhan, Lisa Barrott, Emma…
It’s awards time – call for nominations! We have had lots of positive feedback from the introduction of the awards dinner at the annual conference, and we are now calling…
The 29th BOPA Annual Conference in 2026 will be held at the ICC London Olympia on 2-4 October 2026.
Check out the latest information here: Latest Conference 2026 – BOPA
Everything you need to know
